Scarica l'app Stockscreener
0.84
4.42%
-0.029
Precedente Chiudi:
$0.869
Aprire:
$0.885
Volume 24 ore:
41,460
Relative Volume:
1.61
Capitalizzazione di mercato:
$3.52M
Reddito:
-
Utile/perdita netta:
$-4.69M
Rapporto P/E:
-0.3605
EPS:
-2.33
Flusso di cassa netto:
$-3.81M
1 W Prestazione:
-0.25%
1M Prestazione:
-37.08%
6M Prestazione:
-60.26%
1 anno Prestazione:
-68.18%
Intervallo 1D:
$0.80
$0.90
Intervallo di 1 settimana:
$0.7467
$0.93
Portata 52W:
$0.64
$3.00
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Nome
Lixte Biotechnology Holdings Inc
Settore
Industria
Telefono
310 203 2902
Indirizzo
248 ROUTE 25A, EAST SETAUKET
Confronta LIXT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
0.84 | 3.52M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.49 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.82 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.64 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.89 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.11 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lixte Biotechnology Holdings Inc Borsa (LIXT) Ultime notizie
Lixte Biotechnology (NASDAQ:LIXT) Trading 20.5% Higher – What’s Next? - Defense World
Lixte Biotechnology Converts Preferred Stock to Common - TipRanks
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
LIXTE BIOTECHNOLOGY HOLDINGS, INC. SEC 10-Q Report - TradingView
Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com India
Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 44.0% in March - Defense World
SEC Form 424B4 filed by Lixte Biotechnology Holdings Inc. - Quantisnow
LIXTE Launches New Study to Determine if Certain - GlobeNewswire
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - GlobeNewswire
Major Breakthrough? LIXTE's Cancer Prevention Drug Could Eliminate Pre-Cancerous Cells in Aging Adults - Stock Titan
LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer Trials - Nasdaq
LIXTE Biotechnology Provides Update On Progress with - GlobeNewswire
Major Breakthrough: LIXTE's Cancer Drug Shows Promise in New GSK, Roche Clinical Trials - Stock Titan
Lixte Biotechnology Holdings Inc. (LIXT) reports earnings - Quartz
Lixte Biotechnology revises sarcoma study agreement By Investing.com - Investing.com Australia
Lixte Biotechnology revises sarcoma study agreement - Investing.com
Lixte Biotech ends sales agreement, explores funding options By Investing.com - Investing.com South Africa
Lixte Biotechnology terminates sales agreement with Wallachbeth Capital -March 11, 2025 at 10:35 am EDT - Marketscreener.com
Lixte Biotech ends sales agreement, explores funding options - Investing.com
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form - GlobeNewswire
New Research Reveals Key Mechanism Behind LIXT's Cancer Drug LB-100 - StockTitan
LIXTE Adds Northwestern University’s Lurie Cancer Center as - GlobeNewswire
LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer - Nasdaq
Can LIXTE's Cancer Drug Breakthrough Succeed Where Others Failed? Northwestern Joins Trial - StockTitan
Lixte Biotechnology faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India
Lixte Biotechnology Holdings, Inc. Announces Successful Closure of $1.05 Million Offering - Defense World
Lixte Biotechnology announces closing of $1.05M registered direct offering - Yahoo Finance
LIXTE Biotechnology Announces Closing of $1.05 Million - GlobeNewswire
Lixte Biotechnology Closes $1.1 Million Direct Offering -February 13, 2025 at 11:06 am EST - Marketscreener.com
LIXTE Biotechnology Holdings, Inc. Completes Registered Direct Offering and Private Placement Raising Approximately $1.05 Million - Nasdaq
LIXTE Secures Critical $1.05M Funding: Strategic Move Unlocks Next Growth Phase - StockTitan
LIXTE Biotechnology announces $1.05M registered direct offering; shares fall - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
LIXTE Biotech (LIXT) Secures Fresh Capital: Strategic $1.05M Direct Offering Includes Warrant Sweetener - StockTitan
Lixte Biotechnology Holdings Inc Inc. (LIXT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - GlobeNewswire
Lixte Biotechnology enters agreement for at-the-market stock sale - Investing.com
Lixte Biotechnology Holdings, Inc. Enters into At-the-Market Sales Agreement with WallachBeth Capital, LLC - Defense World
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World
Lixte Biotechnology Holdings, Inc. Vice President and COO Resigns - Defense World
Lixte Biotechnology announces executive departure By Investing.com - Investing.com Nigeria
Lixte Biotechnology announces executive departure - Investing.com
US Penny Stocks To Watch In December 2024 - Simply Wall St
Lixte Biotechnology Holdings Inc Azioni (LIXT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):